Nestlé India Limited
Preview the depth — unlock the full forensic study.
You're reading the free Overview. The full Landscape study, the Lenses, governance and quality scans unlock with Pro — across 5,000 Indian companies.
Briefing
Nestlé India Limited — the brief
Forensic posture: Clean disclosures. The auditor gave Nestlé India a clean bill of health with no flags, but the company has 4 medium-severity related-party transactions worth ₹1.3 Cr in aggregate (licence fees to parent, new sales to a director-linked entity, and a health-science business restructuring) that warrant transparency; financially, the company is fortress-solid with minimal contingent liabilities and excellent earnings quality.
Auditor’s report (CARO 2020)
Auditor’s assessment Clean. Auditor: S.R. Batliboi & Co. LLP. Opinion: Unqualified. Fiscal year FY24-25.
Related-party transactions
Assessment Notable. Disclosed volume of ₹3,562 Cr across 60 related parties. Fiscal year FY24-25.
- Large licence fees paid to Nestlé group entity: General licence fees of ₹8,978.9 million (approx. ₹897.89 Cr) paid to Société des Produits Nestlé S.A. represent ~4.5% of net revenues; while this is a standard arrangement in MNC subsidiaries, the absolute quantum warrants ongoing monitori
- New large sales to KMP-controlled entity Apollo Healthco: Sales of ₹4,891.5 million (approx. ₹489.15 Cr) to Apollo Healthco Limited — an entity controlled by an Independent Director (Ms. Suneeta Reddy) — commenced in FY25 with nil in prior year, creating a material new related-party revenue stream
- All outstanding RPT balances are unsecured and interest-free: The AR explicitly discloses that all outstanding related-party balances (including ₹941.5 million receivable from fellow subsidiaries and ₹252.7 million receivable from KMP-controlled entities) are unsecured and interest-free; while common
- Health science business slump-sold to new associate: The Company transferred its Health Science business via slump sale for ₹2,231.0 million to Dr. Reddy's and Nestlé Health Science Limited — a newly formed 49% associate — in FY25, representing a significant intra-group restructuring transact
Contingent liabilities
Assessment Routine. Total disclosed: ₹501 Cr (12.5% of net worth). Fiscal year FY24-25.
Corporate governance
Board of 8 directors, 63% independent. Chair: Suresh Narayanan. Chair and CEO roles are combined. Statutory auditor: S.R. Batliboi & Co. LLP. Fiscal year FY24-25.
“General licence fees (net of taxes) - Société des Produits Nestlé S.A. 8,978.9”
What retail misses·The sudden ₹489 Cr revenue spike to an Independent Director's company (Apollo Healthco) and the ₹223 Cr health-science restructuring with a new 49% JV don't show up on basic screeners; these appear in the Related Party and contingent disclosures but are rarely highlighted in news or analyst summaries.
Strengths noted in disclosures: Auditor (S.R. Batliboi & Co.) issued unqualified opinion with zero high or material flags — no going-concern doubts or accounting irregularities. · Contingent liabilities total only ₹500.94 Cr, representing 12.5% of net worth; neither item is material — routine capital commitments and minor tax claims. · Earnings quality composite score of 91/100 (Excellent) with no manipulation risk detected; cash flow matches reported profit and profitability ranks in top decile for the consumer sector.
Forensic signal
From the company's own filingsStrong: 52-Week · Size · Weak: Valuation · Yield